Nkarta, Inc.
NASDAQ:NKTXBiotechnology
+$0.09 today
- Market cap
- $82.37M
- Beta
- 0.90
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.35
Volume 0.81M
Average 0.75M
NKTX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Nkarta, Inc.NASDAQ: NKTX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$25.49M, compared with -$29.17M a year earlier. Trailing-twelve-month EBITDA was -$90.7M.
Context
- EBITDA grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +4.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$25.49M-1.4% QoQ
- Last fiscal yearDec 2025
- -$94.89M+4.8% YoY
- LTMMar 2026
- -$90.7M+10.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +12.6% | +100.0% | +87.4 pp |
| 1 year | +4.8% | +100.0% | +95.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (94.89M) USD
- Year-over-year change
- +4.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (94.89M) | +4.8% |
| FY2024 | 2024-12-31 | (99.64M) | +17.3% |
| FY2023 | 2023-12-31 | (120.48M) | -14.1% |
| FY2022 | 2022-12-31 | (105.61M) | -25.3% |
| FY2021 | 2021-12-31 | (84.32M) | — |
EBITDA vs competitors
How NKTX compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +10.7% is the 5th highest of 8, against a peer median of +22.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $449.13M USD | +489.9% | — | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | -$37.68M USD | +23.9% | — | — |
| LTM Mar 2026 | -CHF 63.08M CHF | -8.3% | — | — | |
| LTM Mar 2026 | -$74.38M USD | -70.3% | — | — | |
| LTM Mar 2026 | -$75.99M USD | +22.0% | — | — | |
| LTM Mar 2026 | -$90.7M USD | +10.7% | — | — | |
| LTM Mar 2026 | -$116.42M USD | -1.3% | — | 632.1% | |
| LTM Mar 2026 | -$117.42M USD | +23.4% | — | 1859.1% | |
| Peer median (excluding NKTX) | — | +22.0% | — | 1245.6% | |
Competitors are the stored peer set for NKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 5.87M | 0 | 9.19M |
| Gross Profit | 0 | 0 | (5.87M) | 0 | (9.19M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 63.41M | 90.9M | 90.9M | 96.74M | 90.43M |
| Selling, General & Admin | 23.02M | 28.06M | 34.88M | 31.45M | 31.57M |
| Operating Expenses | 86.43M | 118.96M | 125.78M | 128.19M | 112.01M |
| Depreciation & Amortization | 1.76M | 2.64M | 5.87M | 9.15M | 9.19M |
| EBITDA | (84.32M) | (105.61M) | (120.48M) | (99.64M) | (94.89M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (86.43M) | (118.96M) | (131.65M) | (128.19M) | (121.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 370K | 5.59M | 14.11M | 19.32M | 15.49M |
| Interest Expense | 0 | 5.59M | 0 | 0 | 0 |
| Other Income / Expenses | 354K | 5.12M | 14.15M | 19.4M | 17.12M |
| Income Before Tax | (86.08M) | (113.84M) | (117.5M) | (108.79M) | (104.08M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (86.08M) | (113.84M) | (117.5M) | (108.79M) | (104.08M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.62) | (2.61) | (2.40) | (1.60) | (1.41) |
| EPS (Diluted) | (2.62) | (2.61) | (2.40) | (1.60) | (1.41) |
| Weighted Avg Shares | 32.86M | 43.63M | 49.01M | 67.87M | 73.99M |
| Weighted Avg Shares (Diluted) | 32.86M | 43.63M | 49.01M | 67.87M | 73.99M |
Nkarta, Inc.
NASDAQ:NKTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.